After receiving technical clearance of the electronic common technical document from the FDA, the regulatory review period will begin, the German drug discovery company said.
Jens Schneider-Mergener, CEO of Jerini, said: “We are extremely pleased to have initiated the submission process for icatibant. This underlines our strategy of bringing icatibant to HAE patients in the US as well as in Europe.”